Researchers in China have retracted a 2016 paper in Oncology Letters on the anti-cancer properties of aspirin because, well, it was a disaster from top to bottom.
In the spirit of showing rather than telling, we’ll let the retraction notice do the work:
We would like to retract our article entitled “Aspirin inhibits growth of ovarian cancer by upregulating caspase‑3 and downregulating bcl‑2”, published in Oncology Letters 12, 93‑96, 2016, for the following reasons. First, we found that certain of the results of the study were too preliminary. Secondly, the p53N236S mice were obtained from an unreliable source, and therefore their genetic background may have been uncertain, which could have added to the lack of confidence in the results. Lastly, the manuscript was completed and submitted by the first author, Lin Li, without the prior consent of the other listed co-authors and the corresponding author. The last three co‑authors (FD, XJ and WZ) have confirmed that they were not aware of being listed as co‑authors, and they were not involved either in the research or in submission process. As a result, we have decided to retract the article from publication. All the named authors agree to this retraction. We sincerely apologize for any inconvenience that might result from the retraction of this article.
Other than that, it was fine. Or something.
The paper has been cited six times, according to Clarivate Analytics’ Web of Science.
Hat tip: Rolf Degen
Like Retraction Watch? You can make a tax-deductible contribution to support our growth, follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up for an email every time there’s a new post (look for the “follow” button at the lower right part of your screen), or subscribe to our daily digest. If you find a retraction that’s not in our database, you can let us know here. For comments or feedback, email us at email@example.com.